Aerobiotix, a Miamisburg, Ohio-based global medical company, raised $25m in equity financing.
The round was led by Vivo Capital with participation from Asahi Kasei Ventures.
The company intends to use the funds to accelerate sales, marketing, and new product development.
Founded in 2013 by Dr. David Kirschman, CEO, Aerobiotix makes airborne infection control products that provide real-time, in room solutions for hospitals, ASCs, long term care and office based settings.
The company’s infection control products have been used to support thousands of procedures across multiple surgical specialty disciplines and in over 175 hospitals and multiple long-term care facilities.
Aerobiotix has developed a novel suite of FDA 510(k) cleared hospital-based air decontamination products and its devices are supported by multiple peer-reviewed research studies. Aerobiotix devices, such as the operating-room based ILLUVIA® system, are used by healthcare centers to reduce bacterial and viral contamination, including SARS-CoV-2 and other emerging pathogens.